A Phase 4 interventional study of Collagenase clostridium histolyticum in Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 11th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 4, and was the 9th registered.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
Browse Dupuytren Contracture studies →None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2012.
This study's enrollment of 52 is below the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Median enrollment 76 across the 17 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
10 studies in Dupuytren Contracture by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Dupuytren Contracture by Keenova Therapeutics plc, this one is one of 4 that started in 2012, is the only one in phase 4, and was the 6th registered.
Keenova Therapeutics plc’s Dupuytren Contracture studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 10 in Dupuytren Contracture:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.
Open-label, Phase 4 study in subjects who are currently participating in the long-term follow-up study (ie, AUX-CC-860) in the United States, Australia, or Europe and who have recurrence of contracture (ie, joint contracture increases by at least 20 degrees compared with the Day 30 value after the last injection in a Phase 3 Auxilium-sponsored study and a palpable cord present) in a joint that was effectively treated (ie, reduction in contracture to 5 degrees or less 30 days after the last injection) with AA4500 in a Phase 3 Auxilium-sponsored study.
Subjects who experience recurrence of contracture in one or more effectively treated joints may be enrolled in this retreatment study after the investigator determines subject eligibility and after informed consent has been obtained. The investigator will treat the cord affecting the recurrent joint with up to three injections. Only one recurrent joint will be treated in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have at least one joint with all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
Biological: Collagenase clostridium histolyticum
Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
Biological: Collagenase clostridium histolyticum
up to three 0.58 mg injections
Also known as: XIAFLEX, XIAPEX, AA4500
Clinical Success
Clinical success defined as reduction in fixed-flexion contracture to less than or equal to 5 degrees 30 days after the last injection of AA4500
Time frame: 30 days after last injection
Percent Change From Baseline in Degree of Contracture
Change in fixed-flection contracture measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees
Time frame: Baseline and 30 days after last injection
Change in Range of Motion
Range of motion defined as difference between full flexion angle and full extension angle expressed in degrees
Time frame: Baseline and 30 days after last injection
Physician Global Assessment of Improvement
Physician global assessment of change (improvement) in subject's Dupuytren's contracture
Time frame: 30 days after last injection
Subject Global Assessment of Satisfaction
Subject global assessment of overall treatment satisfaction
Time frame: 30 days after last injection
Recurrence of Contracture
Recurrence of contracture in the joint at day 365 that was successfully treated 30 days after last injection assessed. Recurrence was defined as 20 degree or greater increase of contracture of the treated joint at day 365 or medication intervention of the treated joint between the 2 time points.
Time frame: Day 365
| Milestone | XIAFLEX/XIAPEX |
|---|---|
| Started | 52 |
| Completed | 47 |
| Not completed | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 1 |
| Withdrew: Other | 3 |
Clinical success defined as reduction in fixed-flexion contracture to less than or equal to 5 degrees 30 days after the last injection of AA4500
| percentage of particpants | XIAFLEX/XIAPEX MP Joint | XIAFLEX/XIAPEX PIP Joint |
|---|---|---|
| Clinical Success | 64.5 (45.37 to 80.77) | 45.0 (23.06 to 68.47) |
Change in fixed-flection contracture measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees
| percentage of contracture change | XIAFLEX/XIAPEX MP Joint | XIAFLEX/XIAPEX PIP Joint |
|---|---|---|
| Percent Change From Baseline in Degree of Contracture | 83.24 ± 24.275 | 69.10 ± 26.776 |
Range of motion defined as difference between full flexion angle and full extension angle expressed in degrees
| degrees | XIAFLEX/XIAPEX MP Joint | XIAFLEX/XIAPEX PIP Joint |
|---|---|---|
| Change in Range of Motion | 31.4 ± 17.52 | 26.8 ± 17.39 |
Physician global assessment of change (improvement) in subject's Dupuytren's contracture
| participants | XIAFLEX/XIAPEX MP Joint | XIAFLEX/XIAPEX PIP Joint |
|---|---|---|
| Very much improved | 18 | 12 |
| Much improved | 11 | 5 |
| Minimally improved | 0 | 2 |
| No change | 1 | 1 |
| Minimally worse | 0 | 0 |
| Much worse | 0 | 0 |
| Very much worse | 0 | 0 |
| Not done | 1 | 0 |
Subject global assessment of overall treatment satisfaction
| participants | XIAFLEX/XIAPEX MP Joint | XIAFLEX/XIAPEX PIP Joint |
|---|---|---|
| Very satisfied | 20 | 10 |
| Quite satisfied | 9 | 5 |
| Neither satisfied nor dissatisfied | 1 | 2 |
| Quite dissatisfied | 0 | 1 |
| Very dissatisfied | 0 | 0 |
| Not done | 1 | 2 |
Recurrence of contracture in the joint at day 365 that was successfully treated 30 days after last injection assessed. Recurrence was defined as 20 degree or greater increase of contracture of the treated joint at day 365 or medication intervention of the treated joint between the 2 time points.
| joints | XIAFLEX/XIAPEX |
|---|---|
| Recurrence of Contracture | 6 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XIAFLEX/XIAPEX | — | 4/52 (7.7%) | 44/52 (84.6%) |
| Event | XIAFLEX/XIAPEX |
|---|---|
| Cerebellar infarctionNervous system disorders | 1/52 |
| Acute coronary syndromeCardiac disorders | 1/52 |
| Acute myocardial infarctionCardiac disorders | 1/52 |
| Chest painGeneral disorders | 1/52 |
| Dupuytren's contractureMusculoskeletal and connective tissue disorders | 1/52 |
| UrosepsisInfections and infestations | 1/52 |
| Event | XIAFLEX/XIAPEX |
|---|---|
| Oedema peripheralGeneral disorders | 32/52 |
| ContusionInjury, poisoning and procedural complications | 23/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 16/52 |
| Injection site painGeneral disorders | 10/52 |
| PruritusSkin and subcutaneous tissue disorders | 10/52 |
| Injection site haematomaGeneral disorders | 8/52 |
| LymphadenopathyBlood and lymphatic system disorders | 8/52 |
| Skin lacerationInjury, poisoning and procedural complications | 7/52 |
| Injection site pruritusGeneral disorders | 5/52 |
| Injection site swellingGeneral disorders | 5/52 |
| Age, Categorical(Participants) | XIAFLEX/XIAPEX |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 32 |
| Age, Continuous(Years) | XIAFLEX/XIAPEX |
|---|---|
| Mean | 66.5 ± 9.53 |
| Sex: Female, Male(Participants) | XIAFLEX/XIAPEX |
|---|---|
| Female | 2 |
| Male | 50 |
| Ethnicity (NIH/OMB)(Participants) | XIAFLEX/XIAPEX |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | XIAFLEX/XIAPEX |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 52 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | XIAFLEX/XIAPEX |
|---|---|
| United States | 21 |
| Australia | 21 |
| United Kingdom | 4 |
| Sweden | 6 |
The record gives a start of Mar 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase